Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd (QNTM) is a biopharmaceutical innovator developing therapies for neurodegenerative, neuropsychiatric, and inflammatory disorders. This page aggregates official news and press releases about the company’s clinical advancements, strategic investments, and market-related developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and strategic financial decisions, including partnerships or legal initiatives impacting shareholder value. The curated content spans research breakthroughs, intellectual property updates, and balanced coverage of both pharmaceutical R&D and complementary investment activities.
All content is sourced directly from company communications to ensure accuracy. Visitors can expect coverage of FDA trial phases, compound licensing deals, and portfolio management decisions from Quantum BioPharma’s dual operational segments. Bookmark this page for efficient tracking of material events affecting QNTM’s trajectory in the biotech sector.
Quantum BioPharma (NASDAQ: QNTM) has announced a Business Update Conference Call scheduled for Tuesday, May 6, 2025, at 4:30 p.m. Eastern time. The call will feature CEO Zeeshan Saeed and Head of Finance Jason Sawyer discussing:
- Year-end financial results
- Regulatory initiatives
- Commercial-readiness activities
- Anticipated milestones
The presentation will be available during the webcast and afterward through the company's investor relations section. Participants can join via:
- US Dial-in: 1-877-407-9716
- International: 1-201-493-6779
- Conference Code: 13753539
A replay will be available until August 6, 2025, accessible through US (1-844-512-2921) and international (1-412-317-6671) numbers with pin 13753539.
Quantum BioPharma (NASDAQ: QNTM) has appointed Kevin Malone as an advisor to the Board of Directors. Malone, a second-generation financial advisor with over 40 years of family experience in wealth management, founded Malone Wealth in 2021. He specializes in pattern recognition and data research, focusing on fighting market corruption and naked short selling.
Malone's expertise includes identifying undervalued assets and tactical investment rebalancing. He has established a charitable fund aimed at incorporating financial literacy into the US Public Education System. Zeeshan Saeed, CEO of Quantum BioPharma, welcomed Malone's appointment, particularly highlighting his experience in naked short squeeze strategies and combating stock manipulation.
Quantum BioPharma (NASDAQ: QNTM) has secured a significant legal victory as the Court of Appeal for Ontario dismissed a reconsideration motion filed by Dr. Raza Bokhari, former CEO of FSD Pharma (now Quantum BioPharma). The court's decision upholds awards totaling $180,000 in Quantum's favor.
The dispute stems from Dr. Bokhari's termination for cause in July 2021. Previously, Arbitrator Cunningham rejected Dr. Bokhari's wrongful dismissal claim and awarded the company approximately CDN$2.81 million in arbitration costs plus interest. The U.S. District Court for Eastern Pennsylvania granted judgment in Quantum's favor, including various monetary awards with interest rates ranging from 4% to 6% per annum.
Dr. Bokhari has appealed the U.S. Court order and received a stay after providing a supersedeas bond for USD $2,882,441.48. The final judgment from the United States Court of Appeals for the Third Circuit is pending.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition has formed a strategic partnership with the Asian American Trade Associations Council (AATAC) to expand the retail distribution of unbuzzd™, their alcohol detox beverage.
The partnership focuses on unbuzzd™'s On-the-Go Powder Stick Packs, which are scientifically proven to accelerate blood alcohol level reduction and restore mental alertness. AATAC represents over 50,000 members operating more than 80,000 locations, including major convenience store chains like 7-Eleven, Shell, Circle K, and BP.
This collaboration aims to increase sales and product accessibility across the United States and Puerto Rico, leveraging AATAC's extensive network of convenience stores and their experience in launching successful consumer goods products.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition is launching unbuzzd™, an alcohol detoxification and anti-hangover beverage, in Puerto Rico through FUSION Distribution Group.
unbuzzd™, scientifically validated through a double-blind placebo-controlled crossover study, is designed to accelerate alcohol metabolism and reduce hangover symptoms. The product will be available in single-serve powder stick packs through FUSION's extensive retail network, including major retailers like Walmart, Walgreens, Costco, Sam's, and various supermarket chains.
FUSION Distribution Group, which already distributes notable brands like CELSIUS Energy Drinks and Kin Whiskey, will initially launch unbuzzd™ in Puerto Rico before expanding across the Caribbean region. The product will be available in grocery stores, pharmacies, convenience stores, hotels, bars, and restaurants.
Quantum BioPharma (NASDAQ: QNTM) has partnered with Massachusetts General Hospital (MGH) for a joint clinical study to validate a novel PET imaging technique for monitoring myelin integrity and demyelination in multiple sclerosis (MS) patients.
The study, led by Dr. Pedro Brugarolas and co-investigated by Dr. Eric Klawiter, will evaluate [18F]3F4AP PET scans alongside MRI scans in both progressive and relapsing-remitting MS forms. Previous studies in rodents and monkeys showed [18F]3F4AP's high sensitivity to demyelinated lesions, suggesting its potential as a biomarker for monitoring demyelination changes in response to MS treatments.
This PET imaging technique, using a radiolabeled form of dalfampridine, aims to complement MRI by providing ultra-sensitive and quantitative demyelination assessment. The research is particularly relevant to Quantum's Lucid-MS clinical development program, which has demonstrated myelin sheath protection in animal models.
Quantum BioPharma (NASDAQ: QNTM) has successfully closed the final tranche of its previously announced financing, raising $2.42 million in Debenture Units. This completion brings the total financing to $5 million, following amendments made on January 20, 2025, and improved terms announced on March 7, 2025.
The funds will be allocated to advance research and development of drug candidates, commercialization efforts, and general working capital. The company projects these funds will sustain operations until at least Q1 2027. Additionally, Quantum has initiated the development of rekvry™, a new alcohol misuse treatment designed for emergency and hospital settings, aimed at reducing healthcare costs and resource burden.
Quantum BioPharma (NASDAQ: QNTM) has announced the renewal of two service contracts. The company has extended its agreement with King Tide Media for a one-month term starting April 1, 2025, at a cost of US$15,000. Additionally, they have renewed services with IR Agency for a 60-day period beginning April 1, 2025, for US$50,000.
Quantum BioPharma (NASDAQ:QNTM) has reported strong financial improvements for Q4 and full year 2024. The company's cash position strengthened to $12.1M USD, up from $11.1M in 2023. Operating expenses decreased by 32% to $16.1M, while net loss improved by 18% to $14.9M compared to 2023.
Key developments include:
- Completion of unbuzzd™ clinical trial showing 40% faster reduction in Blood Alcohol Concentration
- Successful Phase 1 trial of Multiple Sclerosis drug Lucid-21-302
- Material Uncertainty Related to Going Concern removed with sufficient working capital through January 2027
- Strategic purchase of $3.5M in Bitcoin and cryptocurrencies
- Dual listing on Upstream exchange
The company's licensee, Celly Nutrition, is exploring an IPO and has secured distribution agreements in Puerto Rico, Caribbean, and parts of Central and South America for unbuzzd.
Quantum BioPharma (NASDAQ: QNTM) reported strong financial improvements for FY2024, removing Material Uncertainty Related to Going Concern. Cash position strengthened to $12.1M USD (up from $11.1M in 2023), with operating expenses reduced by 32% to $16.1M USD.
Key highlights include:
- Net loss improved 18% to $14.9M USD
- Net cash used in operations decreased 36% to $6.9M USD
- Successfully completed clinical trials for unbuzzd™ alcohol detoxification beverage, showing 40% faster BAC reduction
- Completed Phase 1 trial for Multiple Sclerosis drug Lucid-21-302, demonstrating safety and tolerability
- Expanded distribution network through FUSION Distribution Group for Caribbean markets
- Invested $3.5M in cryptocurrencies and dual-listed on Upstream exchange
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
